Company news
Hansoh Pharmaceutical Group Company Limited news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 2, 2026
Inside information - strategic collaboration and license agreement with roche
October 19, 2026
Voluntary announcement - marketing authorization application of Aumolertinib in the EU resubmitted and validated by the EMA
October 11, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 2, 2026
Voluntary announcement - update on the marketing authorization status of aumolertinib in the EU
September 27, 2026
Voluntary announcement - biologics license application of risvutatug rezetecan for injection (HS-20093) for osteosarcoma accepted by the nmpa
September 24, 2026
Notification letter to non-registered holders and request form
September 23, 2026
Notification letter to registered shareholders and reply form
September 23, 2026
Interim report 2026
September 23, 2026
Voluntary announcement - risvutatug rezetecan for injection (HS-20093) for osteosarcoma included in priority review and approval procedure of the nmpa
September 22, 2026
Hansoh Pharmaceutical Group: Pharma announces pivotal phase 3 clinical trial of HS-10374 in the treatment of adults with moderate-to-severe plaque psoriasis met the co-primary endpoints
September 20, 2026
Voluntary announcement - the phase iii clinical study of HS-10374 in the treatment of moderate-to-severe plaque psoriasis has met the co-primary endpoints
September 20, 2026
Voluntary announcement - the clinical trial approval for HS-20197 for injection issued by the national medical products administration
September 16, 2026
Hansoh Pharmaceutical Group: Wclc 2026 | hansoh pharma announces proffered oral presentation of phase i study data of HS-10370 combined with adebrelimab and chemotherapy in advanced kras G12C-mutated nsclc
September 14, 2026
Hansoh Pharmaceutical Group: 2026 Wclc | hansoh pharma announces interim results from phase 3 artemis-008 study of risvutatug rezetecan (HS-20093) in patients with relapsed small cell lung cancer
September 12, 2026
Biologics license application of risvutatug rezetcan (HS-20093) for injection for small cell lung cancer accepted by the nmpa
September 7, 2026
Hansoh Pharmaceutical Group: Pharma announces artemis-011 phase 3 trial of risvutatug rezetecan (HS-20093) met primary endpoint of irc-assessed PFS in osteosarcoma
July 28, 2026
Hansoh Pharmaceutical Group: A mark of excellence!hansohpharmaceutical secures a top three spot among "model industrial enterprises for china’s pharmaceutical R&D pipelines" for the tenth consecutive year.
July 15, 2026
Hansoh Pharmaceutical Group: Pharma announces license collaboration and strategic investment with avere for oral il‑23 asset hs‑20118
July 14, 2026
Hansoh Pharmaceutical Group: Pharma announces artemis-008 trial of risvutatug rezetecan (HS-20093) met its primary endpoint of overall survival in small cell lung cancer
July 10, 2026
Esmo tat asia 2026 | hansoh pharma presents phase 2 data of risvutatug rezetecan (ris-rez) in relapsed or refractory sarcomas
June 18, 2026
Esmo tat asia 2026 | hansoh pharma presented phase i data of HS-20117, an egfr/c-met bispecific antibody, in patients with egfr exon 20 insertion-mutated advanced nsclc
June 18, 2026
Pivotal trial of ameile® plus chemotherapy (AENEAS2) published in the lancet oncology
June 17, 2026
EHA 2026 | hansoh pharma presented data from two clinicalstudies of HS-10382, a novel BCR: : ABL1 allosteric inhibitor, in Chronic Myeloid Leukemia (CML)
June 12, 2026
Sid 2026 | hansoh pharma presented phase 1 data of HS-20118 in healthy adults and psoriasis patients
May 15, 2026
Aacr 2026 | hansoh pharma presented results of HS-10504 (a novel, potent, highly selective, fourth-generation egfr tki) from a first in human phase 1 study in patients with advanced nsclc
April 22, 2026
Aacr 2026 | hansoh pharma presented phase 1 results of risvutatug rezetecan plus adebrelimab in non-squamous nsclc without actionable genomic alterations
April 19, 2026
Aan 2026 | hansoh pharma presented phase 1B/2 data of HS-10506 (a selective orexin-2 receptor antagonist) in insomnia
April 17, 2026
Pharma – xinyue’s third indication approved for marketing for the treatment of generalized myasthenia gravis in adult patients
April 3, 2026
Wcn 2026 | hansoh pharma presented phase 1 data of HS-10542（a complement factor b inhibitor）in healthy participants
March 27, 2026
Elcc 2026 | hansoh pharma presented results of dalmelitinib (HS-10241, a highly selective met-tki) combined with aumolertinib from a phase ib study in patients with met-amplified advanced nsclc post egfr tki
March 26, 2026
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
March 9, 2026
Hansoh Pharmaceutical Group: Olatorepatide (HS-20094) achieves up to 19.3% weight loss at week 48 in phase 3 study with favorable gastrointestinal tolerability
March 6, 2026
Hansoh Pharmaceutical Group: Cancer cell publishes phase 1 lung cancer results of risvutatug rezetecan
March 5, 2026
Asco gu 2026 | hansoh pharma presented phase 2 data of risvutatug rezetecan in metastatic castration-resistant prostate cancer
February 27, 2026
Esgo 2026 | hansoh pharma presented data for mocertatug rezetecan (HS-20089,a B7-H4-targeted adc) in patients with platinum-sensitive ovarian cancer,with one study selected as lba
February 27, 2026
Hansoh Pharmaceutical Group: Pharma announces the new drug application of dalmelitinib mesylate tablets was accepted by the national medical products administration
February 26, 2026
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
February 3, 2026
China nmpa accepts new drug application for HS-10365 capsules for the treatment of ret fusion-positive nsclc
October 23, 2025
Hansoh Pharmaceutical Group: Grants roche an exclusive license to novel CDH17-targeting adc HS-20110
October 16, 2025